Trial Profile
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix, vs Hib-MenC or Priorix Only, in Toddlers (13-14 m) Primed With 3 Doses of Hib (as Part of a DTPa -Containing Vaccine) and MenC-CRM197 Conjugate Vaccines.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Hib-meningococcal vaccine group C conjugate (Primary) ; Measles mumps and rubella virus vaccine
- Indications Haemophilus infections; Measles; Meningococcal group C infections; Mumps; Rubella
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 01 Mar 2010 Results published in the Pediatric Infectious Disease Journal
- 27 Oct 2009 New trial record